Hemodynamic Changes of Patients Receiving Atenolol/Bisoprolol (CHAB)

Hospital Italiano de Buenos Aires

Status and phase: Completed; Phase 4

Conditions: Hypertension; Metabolic Syndrome

Treatments: Drug: Atenolol; Drug: Bisoprolol

Study type: Interventional

Funder types: Other

Identifiers

NCT01939509

1445

Details and patient eligibility

About

At hemodynamic level, the greater affinity of bisoprolol by the beta 1 receptor in theory could improve the peripheral arterial perfusion and could have a greater antihypertensive effect. At the same time, this could carry objectifiable improvements in the vascular tree, such as the level of arterial stiffness.

This study attempts to mark the hemodynamic differences in the same individual with hypertension and metabolic syndrome who will be exposed to both drugs at different moments. Parameters will be objectified with impedance cardiography, pulse wave velocity and central blood pressure assessment before and after taking each one of the drugs. The results will be compared to the baseline data and between themselves.

Enrollment: 80 estimated patients

Sex: All

Ages: 21+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Hypertension
• Metabolic syndrome

Exclusion criteria

• Severe hypertension >180/110
• Secondary hypertension
• Contraindication for betablockers
• Prior treatment with betablockers (up to one month before inclusion)
• History of neoplastic disease
• Patients that do not sign informed consent

Trial design

Primary purpose: Health Services Research

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

80 participants in 1 patient group

Atenolol-Bisoprolol

Experimental group

Treatment:

Drug: Bisoprolol

Drug: Atenolol